Positive phase IIb data for BAF312 (siponimod) in MS

Mayzent is an oral treatment for relapse remitting MS and active secondary progressive MS.
Post Reply
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm

Positive phase IIb data for BAF312 (siponimod) in MS

Post by MSUK » Fri Apr 20, 2012 2:35 am


At the 64th annual meeting of the American Academy of Neurology (AAN) Novartis will present the key results from a phase II dose finding study of its investigational compound BAF312 (siponimod), a selective modulator of the S1P receptor subtypes 1 and 5 (S1P1, 5-R modulator), in MS.

This double-blind placebo-controlled study applied an innovative adaptive trial design to optimally describe the dose response relationship.

A statistically significant dose response relationship could be established....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/

Post Reply
  • Similar Topics
    Last post

Return to “Mayzent (Siponimod)”